ORGO

+ Watchlist + Portfolio

Organogenesis Holdings Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.91
52-Week Range: $1.54 – $7.08
Market Cap: $236.76M
P/E (TTM): —
EPS (TTM): -0.79
Dividend Yield: —

Advanced Metrics

Price/Book: 1.60
PEG Ratio: —
Return on Equity: -25.92%
Return on Assets: -4.11%
Gross Margin: 71.49%
Operating Margin: -119.25%
Profit Margin: -18.40%
Current Ratio: 3.52
Debt/Equity: 0.23
Total Debt: $66.95M
Free Cash Flow: $28.45M
Revenue Growth: -56.70%
Earnings Growth: —
Enterprise Value: $397.48M

ORGO Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$450.89M	$433.14M	$482.04M	$563.03M
Cost of Revenue	$105.02M	$106.48M	$115.74M	$137.52M
Gross Profit	$345.87M	$326.66M	$366.30M	$425.51M
Research & Development	$39.76M	$44.38M	$50.27M	$44.54M
Selling, General & Admin	$283.81M	$269.75M	$294.51M	$326.24M
Operating Expenses	$323.57M	$314.13M	$344.78M	$369.64M
Operating Income	$22.30M	$12.53M	$21.52M	$55.87M
EBITDA	$40.32M	$36.03M	$24.11M	$82.81M
Pretax Income	$20.28M	$10.39M	-$2.81M	$46.97M
Income Tax	$4.75M	$5.45M	-$3.67M	$9.94M
Net Income	$15.53M	$4.95M	$861.00K	$37.03M
Diluted EPS	0.12	0.04	-0.01	0.15
Diluted Shares	132.38M	132.75M	131.67M	130.25M

ORGO Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$102.48M	$103.84M	$135.57M	$93.68M
Receivables	$89.45M	$82.00M	$109.86M	$217.45M
Inventory	$24.78M	$28.25M	$26.22M	$29.63M
Current Assets	$222.61M	$225.04M	$285.94M	$362.19M
Total Assets	$449.36M	$460.02M	$497.89M	$598.73M
Current Liabilities	$75.02M	$80.51M	$77.48M	$100.12M
Long-Term Debt	$66.23M	$60.74M	—	—
Total Debt	$123.79M	$119.35M	$43.31M	$82.14M
Total Liabilities	$183.69M	$181.36M	$112.57M	$164.81M
Retained Earnings	-$45.30M	-$40.97M	-$40.11M	-$3.08M
Shareholders' Equity	$265.67M	$278.66M	$385.32M	$433.92M
Working Capital	$147.59M	$144.53M	$208.46M	$262.06M

ORGO Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	$24.86M	$30.92M	$14.21M	-$10.31M
Capital Expenditure	-$33.90M	-$24.36M	-$10.03M	-$14.15M
Free Cash Flow	-$9.04M	$6.55M	$4.18M	-$24.46M
Depreciation & Amortisation	$18.03M	$23.45M	$25.37M	$26.94M
Stock-Based Compensation	$6.55M	$9.00M	$10.58M	$13.30M
Investing Cash Flow	-$33.90M	-$24.36M	-$10.03M	-$14.15M
Financing Cash Flow	-$2.20M	-$5.50M	$27.64M	-$17.36M
Share Repurchases	$0.00	$0.00	-$25.48M	$0.00
Net Change in Cash	-$11.24M	$1.05M	$31.81M	-$41.82M

ORGO Income statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$100.78M	$150.49M	$225.07M	$36.25M	$42.80M
Cost of Revenue	$27.63M	$36.25M	$49.92M	$25.77M	$23.67M
Gross Profit	$73.15M	$114.24M	$175.15M	$10.48M	$19.13M
Research & Development	$10.39M	$13.22M	$10.29M	$15.16M	$18.30M
Selling, General & Admin	$73.81M	$79.74M	$100.17M	$65.19M	$53.97M
Operating Expenses	$83.98M	$92.59M	$109.92M	$79.37M	$71.31M
Operating Income	-$10.83M	$21.65M	$65.23M	-$68.89M	-$52.18M
EBITDA	-$4.17M	$28.64M	$72.24M	-$56.52M	-$45.59M
Pretax Income	-$11.83M	$21.16M	$63.43M	-$68.47M	-$50.88M
Income Tax	-$2.44M	-$407.00K	$19.73M	-$15.32M	$45.39M
Net Income	-$9.39M	$21.57M	$43.70M	-$53.16M	-$96.27M
Diluted EPS	-0.10	0.11	0.24	-0.44	-0.77
Diluted Shares	126.85M	130.85M	132.21M	127.80M	128.67M

ORGO Balance Sheet statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$73.08M	$63.74M	$93.68M	$91.38M	$46.10M
Receivables	$120.38M	$168.78M	$217.45M	$116.91M	$100.94M
Inventory	$33.04M	$39.58M	$29.63M	$28.43M	$29.28M
Current Assets	$260.22M	$299.75M	$362.19M	$268.50M	$200.30M
Total Assets	$461.13M	$509.83M	$598.73M	$519.99M	$406.45M
Current Liabilities	$65.84M	$90.32M	$100.12M	$76.02M	$56.96M
Total Debt	$40.82M	$40.81M	$82.14M	$70.86M	$66.95M
Total Liabilities	$99.91M	$123.85M	$164.81M	$138.65M	$118.31M
Retained Earnings	-$68.34M	-$46.78M	-$3.08M	-$56.23M	-$152.50M
Shareholders' Equity	$361.22M	$385.98M	$433.92M	$381.35M	$288.13M
Working Capital	$194.38M	$209.43M	$262.06M	$192.48M	$143.34M

ORGO Cash Flow statement, quarterly periods, in USD
USD	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$32.87M	$3.08M	$39.42M	$21.13M	-$31.65M
Capital Expenditure	-$3.64M	-$2.23M	-$4.65M	-$3.15M	-$1.10M
Free Cash Flow	-$36.51M	$844.00K	$34.77M	$17.98M	-$32.75M
Depreciation & Amortisation	$6.66M	$6.99M	$7.01M	$12.37M	$6.59M
Stock-Based Compensation	$2.54M	$3.06M	$4.32M	$3.64M	$3.05M
Investing Cash Flow	-$3.64M	-$2.23M	-$4.65M	-$3.15M	-$1.10M
Financing Cash Flow	-$288.00K	-$10.21M	-$4.81M	-$20.21M	-$12.50M
Net Change in Cash	-$36.80M	-$9.36M	$29.96M	-$2.23M	-$45.26M

Market Snapshot

About

Organogenesis Holdings is a regenerative medicine company focused on developing and commercializing advanced wound care and surgical biologics products. The company manufactures bioactive products derived from human cells and tissues for treating chronic wounds, burns, and surgical applications.